On the recordApril 24, 2013
I would hope--and I will conclude, Mr. Chairman--that the FDA would consider prioritizing its oversight.
Source
congress.govEditor's note · Context
Lowey urges the FDA to prioritize oversight of high-risk compounded products.
Share & report
More from Nita Lowey
Feb 25, 2020
This administration has taken it too far, with a heartless obsession with immigration enforcement.
Sep 24, 2019
I would like to thank my friends, Chairman Price and Ranking Member Diaz-Balart, for holding this hearing today.
Feb 10, 2020
I was optimistic when President Trump said he would clear the market of flavored e-cigarettes.
Feb 10, 2020
When will FDA approve all of the requests of New York State for approval of additional laboratories?
Other voices in this conversation
